MA52618A - Benzamides substitués par 1,3-thiazol-2-yle pour le traitement de maladies associées à la sensibilisation des fibres nerveuses - Google Patents
Benzamides substitués par 1,3-thiazol-2-yle pour le traitement de maladies associées à la sensibilisation des fibres nerveusesInfo
- Publication number
- MA52618A MA52618A MA052618A MA52618A MA52618A MA 52618 A MA52618 A MA 52618A MA 052618 A MA052618 A MA 052618A MA 52618 A MA52618 A MA 52618A MA 52618 A MA52618 A MA 52618A
- Authority
- MA
- Morocco
- Prior art keywords
- yle
- thiazol
- treatment
- diseases associated
- fiber sensitization
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/425—Thiazoles
- A61K31/427—Thiazoles not condensed and containing further heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/506—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
- A61K31/5375—1,4-Oxazines, e.g. morpholine
- A61K31/5377—1,4-Oxazines, e.g. morpholine not condensed and containing further heterocyclic rings, e.g. timolol
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/06—Antiasthmatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/14—Antitussive agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
EP18172409 | 2018-05-15 |
Publications (1)
Publication Number | Publication Date |
---|---|
MA52618A true MA52618A (fr) | 2021-04-21 |
Family
ID=62186254
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
MA052618A MA52618A (fr) | 2018-05-15 | 2019-05-14 | Benzamides substitués par 1,3-thiazol-2-yle pour le traitement de maladies associées à la sensibilisation des fibres nerveuses |
Country Status (16)
Country | Link |
---|---|
US (1) | US20210220358A1 (fr) |
EP (1) | EP3793554A1 (fr) |
JP (1) | JP2021523919A (fr) |
KR (1) | KR20210009341A (fr) |
CN (1) | CN112334132A (fr) |
AU (1) | AU2019269049A1 (fr) |
BR (1) | BR112020022553A2 (fr) |
CA (1) | CA3100099A1 (fr) |
CL (1) | CL2020002939A1 (fr) |
EA (1) | EA202092678A1 (fr) |
JO (1) | JOP20200286A1 (fr) |
MA (1) | MA52618A (fr) |
MX (1) | MX2020012202A (fr) |
SG (1) | SG11202011010YA (fr) |
TW (1) | TWI780329B (fr) |
WO (1) | WO2019219674A1 (fr) |
Families Citing this family (8)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US10174016B2 (en) | 2014-12-09 | 2019-01-08 | Beyer Aktiengesellschaft | 1,3-thiazol-2-yl substituted benzamides |
AU2019353424B2 (en) | 2018-10-05 | 2022-12-08 | Shionogi & Co., Ltd. | Medicine for treating chronic cough |
EP3757103A1 (fr) * | 2019-06-27 | 2020-12-30 | Bayer AG | Analogues de 3-(5-méthyl-1,3-thiazol-2-yl)-n-{(1r)-1-[2-(trifluoro-méthyl)pyrimidin-5-yl]éthyl}benzamide pour le traitement des maladies neurogeniques |
CN113082023B (zh) * | 2019-12-23 | 2024-03-01 | 武汉朗来科技发展有限公司 | P2x3抑制剂和p2x4抑制剂的药物组合及其应用 |
WO2021238834A1 (fr) * | 2020-05-25 | 2021-12-02 | 中国医药研究开发中心有限公司 | Composé arylformamide et son procédé de préparation et son utilisation médicale |
JP2023543066A (ja) * | 2020-09-30 | 2023-10-12 | ヒューマンウェル ヘルスケア (グループ) カンパニー リミテッド | ベンザミド類化合物及びその使用 |
WO2022253943A1 (fr) | 2021-06-04 | 2022-12-08 | Bayer Aktiengesellschaft | Formes cristallines de 3-(5-méthyl-1,3-thiazol-2-yl)-5-[(3r)-tétrahydrofuran-3-yloxy]-n-{(1r)-1-[2-(trifluoro-méthyl)pyrimidin-5-yl]éthyl}-benzamide |
WO2022253945A1 (fr) | 2021-06-04 | 2022-12-08 | Bayer Aktiengesellschaft | Formes posologiques pharmaceutiques comprenant du 3-(5-méthyl-1,3-thiazol-2-yl)-5-[(3r)-tétrahydrofuran-3-yloxy]-n-{(1r)-1-[2-(trifluorométhyl)pyrimidin-5-yl]éthyl}-benzamide |
Family Cites Families (8)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US5023252A (en) | 1985-12-04 | 1991-06-11 | Conrex Pharmaceutical Corporation | Transdermal and trans-membrane delivery of drugs |
US5011472A (en) | 1988-09-06 | 1991-04-30 | Brown University Research Foundation | Implantable delivery system for biological factors |
EP2262766B1 (fr) * | 2008-02-29 | 2015-11-11 | Evotec AG | Composés amides, compositions à base de ces composés et leurs utilisations |
MX367657B (es) | 2013-08-23 | 2019-08-30 | Afferent Pharmaceuticals Inc | Moduladores del receptor p2x3 y p2x2/3 de diaminopiridina para el tratamiento de la tos aguda, sub-aguda o crónica. |
US10174016B2 (en) * | 2014-12-09 | 2019-01-08 | Beyer Aktiengesellschaft | 1,3-thiazol-2-yl substituted benzamides |
US10183937B2 (en) * | 2014-12-09 | 2019-01-22 | Bayer Aktiengesellschaft | 1,3-thiazol-2-yl substituted benzamides |
RS64155B1 (sr) * | 2015-09-29 | 2023-05-31 | Afferent Pharmaceuticals Inc | Diaminopirimidinski modulatori p2x3 i p2x2/3 receptora, za upotrebu u lečenju kašlja |
EA202092680A1 (ru) * | 2018-05-15 | 2021-04-13 | Байер Акциенгезельшафт | 1,3-тиазол-2-ил-замещенные бензамиды для лечения заболеваний, ассоциированных с сенситизацией нервных волокон |
-
2019
- 2019-05-14 KR KR1020207035583A patent/KR20210009341A/ko not_active Application Discontinuation
- 2019-05-14 US US17/055,488 patent/US20210220358A1/en not_active Abandoned
- 2019-05-14 AU AU2019269049A patent/AU2019269049A1/en active Pending
- 2019-05-14 EA EA202092678A patent/EA202092678A1/ru unknown
- 2019-05-14 MA MA052618A patent/MA52618A/fr unknown
- 2019-05-14 WO PCT/EP2019/062332 patent/WO2019219674A1/fr unknown
- 2019-05-14 JP JP2020564269A patent/JP2021523919A/ja active Pending
- 2019-05-14 JO JOP/2020/0286A patent/JOP20200286A1/ar unknown
- 2019-05-14 TW TW108116606A patent/TWI780329B/zh active
- 2019-05-14 EP EP19723792.8A patent/EP3793554A1/fr not_active Withdrawn
- 2019-05-14 MX MX2020012202A patent/MX2020012202A/es unknown
- 2019-05-14 SG SG11202011010YA patent/SG11202011010YA/en unknown
- 2019-05-14 BR BR112020022553-3A patent/BR112020022553A2/pt unknown
- 2019-05-14 CA CA3100099A patent/CA3100099A1/fr active Pending
- 2019-05-14 CN CN201980042853.2A patent/CN112334132A/zh active Pending
-
2020
- 2020-11-12 CL CL2020002939A patent/CL2020002939A1/es unknown
Also Published As
Publication number | Publication date |
---|---|
SG11202011010YA (en) | 2020-12-30 |
EP3793554A1 (fr) | 2021-03-24 |
CL2020002939A1 (es) | 2021-03-05 |
CA3100099A1 (fr) | 2019-11-21 |
KR20210009341A (ko) | 2021-01-26 |
MX2020012202A (es) | 2021-01-29 |
CN112334132A (zh) | 2021-02-05 |
TW201946924A (zh) | 2019-12-16 |
AU2019269049A1 (en) | 2020-11-26 |
TWI780329B (zh) | 2022-10-11 |
JOP20200286A1 (ar) | 2020-11-09 |
US20210220358A1 (en) | 2021-07-22 |
BR112020022553A2 (pt) | 2021-02-02 |
EA202092678A1 (ru) | 2021-04-12 |
JP2021523919A (ja) | 2021-09-09 |
WO2019219674A1 (fr) | 2019-11-21 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
MA52618A (fr) | Benzamides substitués par 1,3-thiazol-2-yle pour le traitement de maladies associées à la sensibilisation des fibres nerveuses | |
MA52616A (fr) | Benzamides à substitution 1,3-thiazol-2-yl pour le traitement de maladies associées à la sensibilisation de fibres nerveuses | |
MA51673A (fr) | Composés destinés au traitement de troubles dépendant de la kinase | |
MA49402A (fr) | Polynucléotides aadc pour le traitement de la maladie de parkinson | |
PH12018500087A1 (en) | 1,1,1-trifluoro-3-hydroxypropan-2-yl carbamate derivatives and 1,1,1-trifluoro-4-hydroxybutan-2-yl carbamate derivatives as magl inhibitors | |
DOP2019000241A (es) | ANTICUERPOS ANTI-PÉPTIDO BETA AMILOIDE N3pGlu Y SUS USOS | |
BR112021016620A2 (pt) | Azepino-indóis e outros heterociclos para o tratamento de distúrbios cerebrais | |
MA52778A (fr) | Méthodes de traitement de troubles associés au récepteur s1p1 | |
MA46018A (fr) | Activateurs d'édition du génome | |
MA55974A (fr) | Composés triaryles pour le traitement de maladies pd-l1 | |
MA51524A (fr) | Composés, compositions et méthodes pour le traitement de maladies impliquant des tissus malades acides ou hypoxiques | |
EA202090510A1 (ru) | Способ лечения бокового амиотрофического склероза придопидином | |
MA49664A (fr) | Combinaisons d'un dérivé de 4-pyrimidinesulfamide avec des principes actifs pour le traitement de maladies liées à l'endothéline | |
MA56387A (fr) | Dérivés de quinazoline-4-one utiles pour le traitement de maladies et de troubles associés à braf | |
BR112018011308A2 (pt) | anticorpos de peptídeo de beta amiloide anti-n3pglu e usos dos mesmos | |
BR112022016382A2 (pt) | Triptaminas específicas para o uso no tratamento de doenças do humor | |
MA51672A (fr) | Composés destinés au traitement des troubles kinases-dépendants | |
MA52415A (fr) | Dérivés de triazine pour le traitement de maladies associées à des neurotrophines | |
MA51738A (fr) | Composés pour le traitement de la douleur | |
MA42953A (fr) | Composés et compositions pour le traitement de troubles oculaires | |
MA54077A (fr) | Polythérapie pour le traitement de maladies hématologiques | |
MA51628A (fr) | Méthode de traitement de troubles de l'équilibre acido-basique | |
EA201990450A1 (ru) | Ингибиторы киназы, содержащей домен с двумя лейциновыми "застежками-молниями" (dlk), для лечения заболевания | |
EP4285993A3 (fr) | Facteur de différentiation de croissance 15 en tant que biomarqueur de metformine | |
MA51136A (fr) | Traitement des maladies monogéniques à l'aide d'un anticorps anti-cd45rc |